Skip to main content
Hope Rugo, MD, Oncology, San Francisco, CA, UCSF Medical Center

HopeS.RugoMD

Oncology • San Francisco, CA

Clinical Professor of Medicine, UCSF

Join to view full profile

Dr. Rugo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Rugo's full profile

Already have an account?

Education & Training

  • University of California (San Francisco)
    University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1987 - 1990
  • University of California (San Francisco)
    University of California (San Francisco)Residency, Internal Medicine, 1984 - 1987
  • Perelman School of Medicine at the University of Pennsylvania
    Perelman School of Medicine at the University of PennsylvaniaClass of 1984

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1986 - 2026
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2009-2014
  • America's Top Doctors for Cancer Castle Connolly, 2005-2013
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Pembrolizumab Monotherapy for Previously Untreated, PD-L1-Positive, Metastatic Triple-Negative Breast Cancer: Cohort B of the Phase II KEYNOTE-086 Study  
    M C Liu, R Nanda, H S Rugo, E P Winer, S Adams, Annals of Oncology
  • Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer  
    Amreen Husain, Sylvia Adams, Hope S Rugo, Carlos H Barrios, Eric P Winer, The New England Journal of Medicine
  • A Pharmacogenetic Prediction Model of Progression‐Free Survival in Breast Cancer Using Genome‐Wide Genotyping Data from CALGB 40502 (Alliance)  
    Hope S Rugo, Francisco Castillos, Beth Overmoyer, Mark J Ratain, Clinical Pharmacology & Therapeutics
  • Join now to see all

Lectures

  • Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor-2-negative (HER2-) advanc... 
    2019 ASCO Annual Meeting - 6/1/2019
  • SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast ca... 
    2019 ASCO Annual Meeting - 6/1/2019
  • The association of early toxicity and outcomes for patients treated with abemaciclib. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
  • Join now to see all

Authored Content

  • Palbociclib plus Endocrine Therapy in Older Women with HR+/HER2– Advanced Breast Cancer: A Pooled Analysis of Randomised PALOMA Clinical StudiesAugust 2018

Press Mentions

  • After Early-Stage Breast Cancer, Interrupting Endocrine Therapy To Become Pregnant Didn’t Raise Risk of Recurrence
    After Early-Stage Breast Cancer, Interrupting Endocrine Therapy To Become Pregnant Didn’t Raise Risk of RecurrenceMay 3rd, 2023
  • Leaders in Breast and Lung Cancer Treatment Join SystImmune Inc's Clinical Science Advisory Committee
    Leaders in Breast and Lung Cancer Treatment Join SystImmune Inc's Clinical Science Advisory CommitteeApril 26th, 2023
  • Totus Medicines Expands Its Scientific Advisory Board with the Addition of Dr. Lewis Cantley, Dr. Hope Rugo, and Dr. Josep Tabernero
    Totus Medicines Expands Its Scientific Advisory Board with the Addition of Dr. Lewis Cantley, Dr. Hope Rugo, and Dr. Josep TaberneroApril 12th, 2023
  • Join now to see all

Professional Memberships

Hospital Affiliations

Dr. Hope Rugo, Dr. Hope Rugo, MD, Dr. H Rugo, Dr. Hope S. Rugo